Based in San Diego-CA, Molecular Response’s platform includes a collection of viable tumor specimens, including tumor, immune, and stromal cells for in vitro and in vivo studies.
TJ Deng, general manager for BioDuro Discovery, said the company is committed to growing into a “complete chemistry and biology provider,” adding, “unique platforms in oncology are a critical centerpiece of that strategy."
According to the contract research and development organization (CDMO), the platform supports various drug discovery oncology and immune-oncology studies, including immunophenotyping screens and xenograft pharmacology studies.
"The Molecular Response acquisition immediately strengthens our capability and provides our clients a continuous set of capability, enabling our customers to start with our chemistry services through preclinical and translational oncology studies, all the way to IND," he said in a press release.
Following the acquisition, terms of which were not disclosed, Molecular Response will operate as a wholly-owned subsidiary of BioDuro and will continue selling its biospecimens to strategic partners.
Molecular Response CEO, Thomas Broudy, PhD will become Executive Vice President, Translational Sciences and Strategy.